TY - JOUR
T1 - A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death
AU - ASSESS-AKI Study Investigators
AU - Ikizler, T. Alp
AU - Parikh, Chirag R.
AU - Himmelfarb, Jonathan
AU - Chinchilli, Vernon M.
AU - Liu, Kathleen D.
AU - Coca, Steven G.
AU - Garg, Amit X.
AU - Hsu, Chi yuan
AU - Siew, Edward D.
AU - Wurfel, Mark M.
AU - Ware, Lorraine B.
AU - Faulkner, Georgia Brown
AU - Tan, Thida C.
AU - Kaufman, James S.
AU - Kimmel, Paul L.
AU - Go, Alan S.
AU - Stokes, John B.
AU - Coca, Steven
AU - Zheng, Sijie
AU - Pravoverov, Leonid
AU - Hsu, Raymond K.
AU - Reeves, W. Brian
AU - Lewis, Julia B.
AU - Ware, Lorraine
AU - Devarajan, Prasad
AU - Krawczeski, Catherine
AU - Bennett, Michael
AU - Zappitelli, Michael
AU - Wurfel, Mark
N1 - Funding Information:
This study was supported by the supplemental American Recovery and Reinvestment Act funds and research grants U01DK082223, U01DK082185, U01DK082192, U01DK082183, U01DK084012, and R01DK098233 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health , U.S. Department of Health and Human Services. This publication was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences , National Institutes of Health, through University of California, San Francisco–Clinical and Translational Science Institute grant UL1RR024131. CRP is also supported by grant R01HL085757. JH is also supported by U2CDK114886, UG3TR002158, and U01DK099923. SGC is also supported by grants R01DK106085 and U01DK106962. AXG is also supported by the Dr. Adam Linton Chair in Kidney Health Analytics, and a Clinician Investigator Award from the Canadian Institutes of Health Research . LBW is also supported by grants R01HL135849 and R01HL103836 . KDL, C-yH, and ASG are also supported by grants R01DK101507, U01DK060902, R01DK101507, K24DK113381, and K24DK92291. EDS is also supported by grant 5K23DK088964.
Funding Information:
The authors would like to thank all of the ASSESS-AKI study participants, research coordinators, and support staff for making this study possible. This study was supported by the supplemental American Recovery and Reinvestment Act funds and research grants U01DK082223, U01DK082185, U01DK082192, U01DK082183, U01DK084012, and R01DK098233 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, U.S. Department of Health and Human Services. This publication was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through University of California, San Francisco?Clinical and Translational Science Institute grant UL1RR024131. CRP is also supported by grant R01HL085757. JH is also supported by U2CDK114886, UG3TR002158, and U01DK099923. SGC is also supported by grants R01DK106085 and U01DK106962. AXG is also supported by the Dr. Adam Linton Chair in Kidney Health Analytics, and a Clinician Investigator Award from the Canadian Institutes of Health Research. LBW is also supported by grants R01HL135849 and R01HL103836. KDL, C-yH, and ASG are also supported by grants R01DK101507, U01DK060902, R01DK101507, K24DK113381, and K24DK92291. EDS is also supported by grant 5K23DK088964. The opinions expressed in this report do not necessarily reflect those of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institutes of Health, the Department of Health and Human Services or the United States government. The lead author (TAI) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained. TAI, CRP, JH, VMC, KDL, SGC, AXG, C-yH, EDS, MMW, GBF, TCT, JSK, PLK, and ASG conceived and designed the study. TAI, CRP, JH, VMC, KDL, SGC, AXG, C-yH, EDS, MMW, LBW, GBF, TCT, JSK, PLK, and ASG analyzed and interpreted data. TAI, VMC, and ASG drafted the manuscript. CRP, JH, KDL, SGC, AXG, C-yH, EDS, MMW, LBW, GBF, TCT, JSK, and PLK revised it critically for important intellectual content. All authors provided final approval of the version to be published. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. ASG is the guarantor.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2021/2
Y1 - 2021/2
N2 - Acute kidney injury (AKI) has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events although previous studies have important limitations. To further examine this, we prospectively studied adults from four clinical centers surviving three months and more after hospitalization with or without AKI who were matched on center, pre-admission CKD status, and an integrated priority score based on age, prior cardiovascular disease or diabetes mellitus, preadmission estimated glomerular filtration rate (eGFR) and treatment in the intensive care unit during the index hospitalization between December 2009-February 2015, with follow-up through November 2018. All participants had assessments of kidney function before (eGFR) and at three months and annually (eGFR and proteinuria) after the index hospitalization. Associations of AKI with outcomes were examined after accounting for pre-admission and three-month post-discharge factors. Among 769 AKI (73% Stage 1, 14% Stage 2, 13% Stage 3) and 769 matched non-AKI adults, AKI was associated with higher adjusted rates of incident CKD (adjusted hazard ratio 3.98, 95% confidence interval 2.51-6.31), CKD progression (2.37,1.28-4.39), heart failure events (1.68, 1.22-2.31) and all-cause death (1.78, 1.24-2.56). AKI was not associated with major atherosclerotic cardiovascular events in multivariable analysis (0.95, 0.70-1.28). After accounting for degree of kidney function recovery and proteinuria at three months after discharge, the associations of AKI with heart failure (1.13, 0.80-1.61) and death (1.29, 0.84-1.98) were attenuated and no longer significant. Thus, assessing kidney function recovery and proteinuria status three months after AKI provides important prognostic information for long-term clinical outcomes.
AB - Acute kidney injury (AKI) has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events although previous studies have important limitations. To further examine this, we prospectively studied adults from four clinical centers surviving three months and more after hospitalization with or without AKI who were matched on center, pre-admission CKD status, and an integrated priority score based on age, prior cardiovascular disease or diabetes mellitus, preadmission estimated glomerular filtration rate (eGFR) and treatment in the intensive care unit during the index hospitalization between December 2009-February 2015, with follow-up through November 2018. All participants had assessments of kidney function before (eGFR) and at three months and annually (eGFR and proteinuria) after the index hospitalization. Associations of AKI with outcomes were examined after accounting for pre-admission and three-month post-discharge factors. Among 769 AKI (73% Stage 1, 14% Stage 2, 13% Stage 3) and 769 matched non-AKI adults, AKI was associated with higher adjusted rates of incident CKD (adjusted hazard ratio 3.98, 95% confidence interval 2.51-6.31), CKD progression (2.37,1.28-4.39), heart failure events (1.68, 1.22-2.31) and all-cause death (1.78, 1.24-2.56). AKI was not associated with major atherosclerotic cardiovascular events in multivariable analysis (0.95, 0.70-1.28). After accounting for degree of kidney function recovery and proteinuria at three months after discharge, the associations of AKI with heart failure (1.13, 0.80-1.61) and death (1.29, 0.84-1.98) were attenuated and no longer significant. Thus, assessing kidney function recovery and proteinuria status three months after AKI provides important prognostic information for long-term clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85091406371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091406371&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.06.032
DO - 10.1016/j.kint.2020.06.032
M3 - Article
C2 - 32707221
AN - SCOPUS:85091406371
SN - 0085-2538
VL - 99
SP - 456
EP - 465
JO - Kidney International
JF - Kidney International
IS - 2
ER -